| Morabito, Alessandro |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Active, not recruiting | 2 | 108 | Europe | paclitaxel, carboplatin, cetuximab | National Cancer Institute, Naples | Cervical Cancer | 12/24 | 12/24 | | |
|
| Not yet recruiting | 2 | 206 | Europe | Atezolizumab, Bevacizumab | Fondazione Ricerca Traslazionale | Non-small-cell Lung Cancer Patients | 05/22 | 04/23 | | |
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC |
|
|
| Not yet recruiting | 2 | 126 | Europe | Pembrolizumab Injectable Product | University of Turin, Italy | Non Small Cell Lung Cancer Patients | 01/23 | 01/23 | | |
MILES-5, NCT03975114: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC |
|
|
| Recruiting | 2 | 460 | Europe | Chemotherapy, Durvalumab, Tremelimumab | National Cancer Institute, Naples, University of Campania "Luigi Vanvitelli", AstraZeneca | Carcinoma, Non-Small-Cell Lung | 12/23 | 06/24 | | |
| Recruiting | 2 | 170 | Europe | Osimertinib, Tagrisso, Dacomitinib, Vizimpro | Fondazione Ricerca Traslazionale, Pfizer srl | NSCLC | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 16 | Europe | ziconotide | National Cancer Institute, Naples | Pain, Neuropathic Pain, Intractable Pain, Cancer | 12/24 | 12/24 | | |
THOR, NCT05623319: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) |
|
|
| Recruiting | 2 | 60 | Europe | Pembrolizumab/Olaparib | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Merck Sharp & Dohme LLC | SCLC,Extensive Stage | 08/26 | 08/26 | | |
NCT04416672: Validation of the Italian Version of the PRO-CTCAE |
|
|
| Recruiting | N/A | 3675 | Europe | PRO-CTCAE items | National Cancer Institute, Naples | Malignant Neoplasms | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 400 | Europe | | National Cancer Institute, Naples | Ovarian Cancer | 11/24 | 11/24 | | |
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC |
|
|
| Recruiting | N/A | 300 | Europe | Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab | University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
PETRA, NCT02035683: PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy |
|
|
| Active, not recruiting | N/A | 220 | Europe | PET/CT | National Cancer Institute, Naples | Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB | 12/24 | 12/24 | | |
